Psyence Biomedical (NASDAQ:PBM) Trading Up 4.9% – Time to Buy?

Psyence Biomedical Ltd. (NASDAQ:PBM)’s stock price shot up 4.9% during trading on Friday . The stock traded as high as $6.85 and last traded at $6.63. 134,407 shares changed hands during trading, an increase of 135% from the average session volume of 57,191 shares. The stock had previously closed at $6.32.

Wall Street Analysts Forecast Growth

Several research firms have recently weighed in on PBM. Wall Street Zen raised Psyence Biomedical to a “hold” rating in a research note on Saturday, June 6th. Weiss Ratings reissued a “sell (e+)” rating on shares of Psyence Biomedical in a research report on Friday, July 17th. One research analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, the company has an average rating of “Sell”.

Psyence Biomedical Price Performance

The firm has a 50-day simple moving average of $3.97 and a 200 day simple moving average of $3.89. The company has a market capitalization of $15.18 million, a PE ratio of 0.26 and a beta of 1.72.

Psyence Biomedical (NASDAQ:PBM) last posted its earnings results on Monday, June 22nd. The company reported ($0.41) earnings per share (EPS) for the quarter.

Psyence Biomedical Company Profile

Psyence Biomedical Ltd. (NASDAQ: PBM) is a clinical-stage biotechnology company focused on developing psychedelic-based therapeutics for mental health conditions. The company’s research centers on naturally derived psilocybin and its potential use in medically supervised treatment programs.

Its lead development program is designed to evaluate psilocybin-assisted therapy for adjustment disorder in patients with cancer. Psyence Biomedical’s activities include drug development, clinical research and work with external partners to advance psychedelic medicines toward potential regulatory approval and commercialization.

The company became publicly traded on Nasdaq in February 2024 following a business combination with Newcourt Acquisition Corp.